ATE259651T1 - Verwendung von keratinocyten-wachstumsfaktor-2 - Google Patents

Verwendung von keratinocyten-wachstumsfaktor-2

Info

Publication number
ATE259651T1
ATE259651T1 AT97913676T AT97913676T ATE259651T1 AT E259651 T1 ATE259651 T1 AT E259651T1 AT 97913676 T AT97913676 T AT 97913676T AT 97913676 T AT97913676 T AT 97913676T AT E259651 T1 ATE259651 T1 AT E259651T1
Authority
AT
Austria
Prior art keywords
growth factor
keratinocyte growth
kgf
pancreas
gums
Prior art date
Application number
AT97913676T
Other languages
English (en)
Inventor
David L Lacey
Thomas R Ulich
Dimitry M Danilenko
Catherine L Farrell
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE259651T1 publication Critical patent/ATE259651T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT97913676T 1996-10-15 1997-10-15 Verwendung von keratinocyten-wachstumsfaktor-2 ATE259651T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2849596P 1996-10-15 1996-10-15
US3225396P 1996-12-06 1996-12-06
US3345796P 1996-12-10 1996-12-10
PCT/US1997/018667 WO1998016243A1 (en) 1996-10-15 1997-10-15 Uses of keratinocyte growth factor-2

Publications (1)

Publication Number Publication Date
ATE259651T1 true ATE259651T1 (de) 2004-03-15

Family

ID=27363283

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97913676T ATE259651T1 (de) 1996-10-15 1997-10-15 Verwendung von keratinocyten-wachstumsfaktor-2

Country Status (10)

Country Link
EP (1) EP0941110B1 (de)
JP (1) JP4270580B2 (de)
AT (1) ATE259651T1 (de)
AU (1) AU725509B2 (de)
CA (1) CA2268741C (de)
DE (2) DE69727691T2 (de)
DK (1) DK0941110T3 (de)
ES (2) ES2216134T3 (de)
PT (1) PT941110E (de)
WO (1) WO1998016243A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
EP1041996A4 (de) 1997-12-22 2003-05-14 Human Genome Sciences Inc Keratinozyten wachstumsfaktor-2 formulierungen
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
AU5593200A (en) * 1999-06-02 2000-12-18 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
NZ516897A (en) * 1999-07-02 2004-01-30 Human Genome Sciences Inc Polynucleotides and associated polypeptides for KGF-2 (also known as Fibroblast Growth Factor 12) to promote and accelerate internal and external wound healing
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220641B1 (hu) * 1993-03-26 2002-03-28 Amgen Inc. Keratinocita növekedési faktor alkalmazása
DK0815115T3 (da) * 1995-02-14 2003-09-15 Human Genome Sciences Inc Keratinocytvækstfaktor-2
AU7248896A (en) * 1995-10-11 1997-04-30 Chiron Corporation Combination pdgf, kgf, igf and igfbp for wound healing
EP0859836A1 (de) * 1995-10-13 1998-08-26 Purdue Research Foundation Verbesserung der qualität von früchten durch hemmung der produktion von lipoxygenase in diesen früchten

Also Published As

Publication number Publication date
WO1998016243A1 (en) 1998-04-23
CA2268741A1 (en) 1998-04-23
ES2216134T3 (es) 2004-10-16
JP2001506586A (ja) 2001-05-22
CA2268741C (en) 2007-04-24
DE69727691T2 (de) 2004-07-22
DE69727691D1 (de) 2004-03-25
JP4270580B2 (ja) 2009-06-03
EP0941110A1 (de) 1999-09-15
DE69738336D1 (de) 2008-01-10
PT941110E (pt) 2004-07-30
EP0941110B1 (de) 2004-02-18
ES2297286T3 (es) 2008-05-01
AU725509B2 (en) 2000-10-12
AU5080698A (en) 1998-05-11
DE69738336T2 (de) 2008-04-03
DK0941110T3 (da) 2004-06-01

Similar Documents

Publication Publication Date Title
NO953781D0 (no) Terapeutisk anvendelse av keratinocyttvekstfaktor
Nishimura et al. Auricular prostheses and osseointegrated implants: UCLA experience
FR2721198B1 (fr) Prothèse implantable souple, utilisée en chirurgie pour l'augmentation de volume ou la reconstruction des tissus mous, notamment prothèse mammaire.
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
DK0637933T3 (da) Fremgangsmåde til behandling af organer og væv
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
DE69738336D1 (de) Verwendung von keratinocyte growth factor-2
DK1007566T3 (da) Terapeutisk anvendelse af SMR1-protein og aktive derivater deraf
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
CA2218333A1 (en) Surgical method for rejuvenating or reshaping body members by bone grafting _______________________________________________________
DK0821969T3 (da) Medicinsk sammensætning omfattende TCF-II
Shields et al. Hydroxyapatite orbital implant after enucleation for intraocular tumors
RU2085163C1 (ru) Способ хирургической реконструкции наружного слухового прохода при его рубцовых стриктурах и облитерациях
RU1804797C (ru) Способ эндоссальной имплантации
RU97114014A (ru) Способ предупреждения послеоперационных осложнений при имплантации искусственного хрусталика
RU93035257A (ru) Способ лечения болезни пайра
UA31468A (uk) Спосіб хірургічного лікування рефлюксної хвороби стравоходу
UA10150A (uk) Спосіб хірургічного лікування низькорозташованих невидалимих виразок дванадцятипалої кишки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0941110

Country of ref document: EP

EEIH Change in the person of patent owner